Although recent advances in biomarkers for mitochondrial diseases have established the effectiveness of fibroblast growth factor 21 (FGF21)31 and growth/differentiation factor 15 (GDF15)32, the regain of wild-type mtDNA and the removal of mutation burden in affected cells should be an optimal indicator of a successful cure. This evidence concerns the gene FGF21 and inborn mitochondrial metabolism disorder.